Loading
A phase 3 trial testing JSKN003 in HR-positive / HER2-negative breast cancer, now recruiting.
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects is a phase 3 interventional study registered as NCT06079983, led by Jiangsu Alphamab Biopharmaceuticals, and recruiting on the registry. Official title: A Phase 3, Multicenter, Randomised, Open-Label, Active-Controlled Trial Of JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects. Planned enrolment is 400 participants (estimated). The study started in 2023-12-01 and primary completion is expected in 2026-04-01. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares JSKN003, Alphamab Oncology.
Shares HER2-low and HER2-ultralow metastatic breast cancer, HR-positive / HER2-negative breast cancer.
Shares HER2-low and HER2-ultralow metastatic breast cancer, HR-positive / HER2-negative breast cancer.
Shares HER2-low and HER2-ultralow metastatic breast cancer, HR-positive / HER2-negative breast cancer.
Shares HER2-low and HER2-ultralow metastatic breast cancer, HR-positive / HER2-negative breast cancer.
Shares HER2-low and HER2-ultralow metastatic breast cancer, HR-positive / HER2-negative breast cancer.
Shares Alphamab Oncology, HR-positive / HER2-negative breast cancer.
Shares HER2-low and HER2-ultralow metastatic breast cancer, HR-positive / HER2-negative breast cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/